AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19538690 — intervention group
Group type: EXPERIMENTAL
Intervention: Group psychoeducation trial
Number of subjects: 19
Study 19538690 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 19
Study 19538690 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive psychotherapies
Number of subjects: 19
Study 17426802 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium 0.10 mg.kg(‐1)
Number of subjects: 120
Study 17426802 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium 0.15 mg.kg(‐1)
Number of subjects: 120
Study 17426802 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.60 mg.kg(‐1)
Number of subjects: 120
Study 17426802 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.90 mg.kg(‐1)
Number of subjects: 120
Study 15589220 — intervention group
Group type: EXPERIMENTAL
Intervention: Gross motor (GM) activity group (bone loading, large muscle exercises)
Number of subjects: 0
Study 15589220 — intervention group
Group type: COMPARATOR
Intervention: Fine motor (FM) activity group (arts and crafts program)
Number of subjects: 0
Study 15589220 — intervention group
Group type: EXPERIMENTAL
Intervention: Gross motor (GM) activity group
Number of subjects: 0
Study 15589220 — intervention group
Group type: COMPARATOR
Intervention: Fine motor (FM) activity group
Number of subjects: 0
Study 15589220 — intervention group
Group type: EXPERIMENTAL
Intervention: Gross motor (GM) group
Number of subjects: 0
Study 15589220 — intervention group
Group type: COMPARATOR
Intervention: Fine motor (FM) group
Number of subjects: 0
Study 11576567 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sulindac (100 mg) every 12 hours until 34 weeks' gestation
Number of subjects: 95
Study 11576567 — intervention group
Group type: COMPARATOR
Intervention: Placebo every 12 hours until 34 weeks' gestation
Number of subjects: 95
Study 9663440 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol-containing chewing gum
Number of subjects: 30
Study 9663440 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol/sorbitol-containing chewing gum
Number of subjects: 30
Study 9663440 — intervention group
Group type: COMPARATOR
Intervention: Sucrose-sweetened chewing gum
Number of subjects: 30
Study 7820328 — intervention group
Group type: EXPERIMENTAL
Intervention: Test drug (piracetam)
Number of subjects: 16
Study 7820328 — intervention group
Group type: COMPARATOR
Intervention: Reference drug (piracetam)
Number of subjects: 16
Study 3344179 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-fortified formulas
Number of subjects: 0
Study 3344179 — intervention group
Group type: COMPARATOR
Intervention: Non-iron-fortified formulas
Number of subjects: 0
Study 1824271 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplantation (BMT) after conditioning with cyclophosphamide (CY) total body irradiation (TBI) plus (n = 27), VP‐16‐TBI (n = 23), and CY‐TBI and ARA‐C (n = 1)
Number of subjects: 51
Study 1824271 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplantation (BMT)
Number of subjects: 51
Study 787460 — intervention group
Group type: EXPERIMENTAL
Intervention: Betahistine (16 mg t.i.d.)
Number of subjects: 22
Study 787460 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 787460 — intervention group
Group type: EXPERIMENTAL
Intervention: Betahistine
Number of subjects: 22
Study 30908420 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortex approach
Number of subjects: 67
Study 30908420 — intervention group
Group type: COMPARATOR
Intervention: ASA algorithm
Number of subjects: 67
Study 29280453 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical OTD70DERM (RGTA)
Number of subjects: 76
Study 29280453 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 26523032 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept (ABA)
Number of subjects: 40
Study 26523032 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 23175561 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine IPTp
Number of subjects: 65
Study 23175561 — intervention group
Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine
Number of subjects: 65
Study 21605121 — intervention group
Group type: EXPERIMENTAL
Intervention: Enactive encoding
Number of subjects: 0
Study 21605121 — intervention group
Group type: COMPARATOR
Intervention: Verbal encoding
Number of subjects: 0
Study 21605121 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated learning
Number of subjects: 0
Study 21605121 — intervention group
Group type: EXPERIMENTAL
Intervention: Task repetition
Number of subjects: 0
Study 19539211 — intervention group
Group type: EXPERIMENTAL
Intervention: Prochymal(R) at a dose of either 2 or 8 million MSCs/kg in combination with corticosteroids
Number of subjects: 32
Study 19539211 — intervention group
Group type: COMPARATOR
Intervention: Prochymal(R) at a dose of either 2 or 8 million MSCs/kg
Number of subjects: 32
Study 16927304 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride 3.5 mg
Number of subjects: 81
Study 16927304 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg
Number of subjects: 81
Study 16927304 — intervention group
Group type: COMPARATOR
Intervention: No therapy (Control)
Number of subjects: 81
Study 15322856 — intervention group
Group type: EXPERIMENTAL
Intervention: IVT(+50%DeltaT)
Number of subjects: 12
Study 15322856 — intervention group
Group type: EXPERIMENTAL
Intervention: IVT
Number of subjects: 12
Study 15322856 — intervention group
Group type: EXPERIMENTAL
Intervention: IVT(‐50%DeltaT)
Number of subjects: 12
Study 15322856 — intervention group
Group type: COMPARATOR
Intervention: Passive recovery
Number of subjects: 12
Study 11455982 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha2a
Number of subjects: 249
Study 9737221 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-site atrial pacing
Number of subjects: 9
Study 9737221 — intervention group
Group type: COMPARATOR
Intervention: Single-site atrial pacing
Number of subjects: 9
Study 9737221 — intervention group
Group type: COMPARATOR
Intervention: Support-only pacing
Number of subjects: 9
Study 8069675 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine
Number of subjects: 11
Study 8069675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 3354254 — intervention group
Group type: EXPERIMENTAL
Intervention: Paediatric attenuated influenza vaccine (two doses, intranasally, 1 month apart)
Number of subjects: 43
Study 29307094 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter with individualized fracture risk and educational brochure
Number of subjects: 7749
Study 29307094 — intervention group
Group type: COMPARATOR
Intervention: Usual care only (control)
Number of subjects: 7749
Study 28704363 — intervention group
Group type: EXPERIMENTAL
Intervention: U-MDT (dapsone+rifampicin+clofazimine for six months)
Number of subjects: 613
Study 28704363 — intervention group
Group type: COMPARATOR
Intervention: R-MDT (dapsone+rifampicin+clofazimine for 12 months)
Number of subjects: 613
Study 28704363 — intervention group
Group type: EXPERIMENTAL
Intervention: U-MDT
Number of subjects: 613
Study 28704363 — intervention group
Group type: COMPARATOR
Intervention: R-MDT
Number of subjects: 613
Study 26222759 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy (lavender oil) in addition to standard medical treatment (diclofenac sodium, 75 mg intramuscularly)
Number of subjects: 100
Study 26222759 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy (diclofenac sodium, 75 mg intramuscularly)
Number of subjects: 100
Study 24218347 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth intervention with diabetes educator nurse via in-home broadband communication device
Number of subjects: 12
Study 24218347 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth intervention
Number of subjects: 12
Study 21443293 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination Behavioral Intervention (CBI) only
Number of subjects: 1383
Study 21443293 — intervention group
Group type: COMPARATOR
Intervention: Study medications (naltrexone, acamprosate, naltrexone + acamprosate, placebo) with medication management (MM)
Number of subjects: 1383
Study 19015204 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus ointment 0.03% applied once daily, 3 times per week
Number of subjects: 206
Study 19015204 — intervention group
Group type: COMPARATOR
Intervention: Vehicle applied once daily, 3 times per week
Number of subjects: 206
Study 16818032 — intervention group
Group type: EXPERIMENTAL
Intervention: P supplementation started the day before oocyte retrieval (Group A)
Number of subjects: 300
Study 16818032 — intervention group
Group type: EXPERIMENTAL
Intervention: P supplementation started on the day of oocyte retrieval (Group B)
Number of subjects: 300
Study 16818032 — intervention group
Group type: EXPERIMENTAL
Intervention: P supplementation started 1 day after egg retrieval (Group C)
Number of subjects: 300
Study 12647487 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy
Number of subjects: 0
Study 12647487 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous combined hormone replacement therapy (HRT)
Number of subjects: 0
Study 11561118 — intervention group
Group type: EXPERIMENTAL
Intervention: Active homeopathy (6cH and/or 30cH dilutions)
Number of subjects: 112
Study 11561118 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 11561118 — intervention group
Group type: EXPERIMENTAL
Intervention: Active homeopathy
Number of subjects: 112
Study 9782217 — intervention group
Group type: EXPERIMENTAL
Intervention: Dey combination solution (albuterol-ipratropium)
Number of subjects: 863
Study 8145958 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 100 mg once daily for 4 weeks
Number of subjects: 20
Study 8145958 — intervention group
Group type: COMPARATOR
Intervention: Griseofulvin 500 mg once daily for 4 weeks
Number of subjects: 20
Study 3139877 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate 10 mg IM weekly
Number of subjects: 40
Study 3139877 — intervention group
Group type: COMPARATOR
Intervention: Sodium aurothiomalate (GSTM) 50 mg IM weekly
Number of subjects: 40
Study 31532277 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (CT) involving intramuscular testosterone injection and testosterone ointment application
Number of subjects: 43
Study 31532277 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular injection monotherapy (IMIM)
Number of subjects: 43
Study 30529119 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical heparin treatment
Number of subjects: 66
Study 30529119 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 66
Study 27618796 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg intravenous amisulpride
Number of subjects: 40
Study 27618796 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg intravenous amisulpride
Number of subjects: 40
Study 27618796 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin (positive control)
Number of subjects: 40
Study 27618796 — intervention group
Group type: COMPARATOR
Intervention: Placebo (negative control)
Number of subjects: 40
Study 26091244 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted TIV (aTIV)
Number of subjects: 197
Study 26091244 — intervention group
Group type: COMPARATOR
Intervention: TIV
Number of subjects: 197
Study 26091244 — intervention group
Group type: EXPERIMENTAL
Intervention: aTIV after control vaccine
Number of subjects: 197
Study 26091244 — intervention group
Group type: COMPARATOR
Intervention: TIV-TIV regimen
Number of subjects: 197
Study 26091244 — intervention group
Group type: COMPARATOR
Intervention: TIV-aTIV mixed regimens
Number of subjects: 197
Study 24334642 — intervention group
Group type: COMPARATOR
Intervention: Traditional written PtGA and GH assessments
Number of subjects: 300
Study 24334642 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal assessments administered in-person
Number of subjects: 300
Study 24334642 — intervention group
Group type: EXPERIMENTAL
Intervention: Health literacy (HL)
Number of subjects: 300
Study 21937041 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral intervention (AIDS Risk Reduction Model)
Number of subjects: 409
Study 21937041 — intervention group
Group type: COMPARATOR
Intervention: Enhanced counseling
Number of subjects: 409
Study 19294693 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (ATV) 80 mg/dL for two months (n = 14)
Number of subjects: 25
Study 19294693 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (CT) for two months (n = 11)
Number of subjects: 25
Study 17180553 — intervention group
Group type: EXPERIMENTAL
Intervention: Transobturator tape (TOT) procedure
Number of subjects: 100
Study 17180553 — intervention group
Group type: COMPARATOR
Intervention: Burch colposuspension procedure
Number of subjects: 100
Study 15470336 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg sildenafil
Number of subjects: 8
Study 15470336 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mL red wine (13.5% by volume)
Number of subjects: 8
Study 15470336 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of sildenafil and red wine
Number of subjects: 8
Study 11347776 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient geriatric evaluation and management (GEM)
Number of subjects: 568
Study 11347776 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 568
Study 9475863 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 0
Study 9475863 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 0
Study 9475863 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for lidocaine study)
Number of subjects: 0
Study 9475863 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for atropine study)
Number of subjects: 0
Study 7710400 — intervention group
Group type: EXPERIMENTAL
Intervention: Teller Acuity Cards
Number of subjects: 69
Study 7710400 — intervention group
Group type: COMPARATOR
Intervention: Snellen visual acuity (gold standard)
Number of subjects: 69
Study 2693405 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine 40 mg t.i.d.
Number of subjects: 192
Study 2693405 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study 912324 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestrogen treatment
Number of subjects: 72
Study 912324 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium treatment
Number of subjects: 72
Study 912324 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 72
Study 31994752 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision-making tool generating personalized predictions of risks and benefits from TJR based on patient-reported outcomes, clinical and demographic data.
Number of subjects: 0
Study 31994752 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified, details not available.
Number of subjects: 0
Study 30905430 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral weight loss intervention with weekly self-monitoring, tailored feedback on diet and exercise goals, and dietitian and provider counseling.
Number of subjects: 306
Study 30905430 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care).
Number of subjects: 306
Study 30905430 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral weight loss intervention.
Number of subjects: 306
Study 27838273 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive working memory training and mindfulness meditation training
Number of subjects: 60
Study 27838273 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive working memory training
Number of subjects: 60
Study 27838273 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training (Adaptive WM training + MMP)
Number of subjects: 60
Study 27838273 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 60
Study 25784358 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab monotherapy (RM)
Number of subjects: 75
Study 25784358 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab plus ketorolac
Number of subjects: 75
Study 25784358 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab plus verteporfin photodynamic therapy (RV)
Number of subjects: 75
Study 24026876 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin/pirarubicin (CITA) chemotherapy
Number of subjects: 331
Study 24026876 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDC) with stem cell transplantation (SCT)
Number of subjects: 331
Study 24026876 — intervention group
Group type: COMPARATOR
Intervention: CITA regimen
Number of subjects: 331
Study 24026876 — intervention group
Group type: COMPARATOR
Intervention: HDC with SCT
Number of subjects: 331
Study 21415071 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-regional pro-adrenomedullin (MR-proADM)
Number of subjects: 214
Study 19154270 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam 20 mg orally for 3 days before orthodontic activation
Number of subjects: 36
Study 19154270 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam 20 mg orally for 3 days after orthodontic activation
Number of subjects: 36
Study 19154270 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 days
Number of subjects: 36
Study 17410029 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine (G) 1250 mg/m, given on days 1 and 14, repeated every 28 days for up to four cycles.
Number of subjects: 90
Study 17410029 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine-carboplatin (GCb) 1250 mg/m of G plus carboplatin area under the curve of 3, given on days 1 and 14, repeated every 28 days for up to four cycles.
Number of subjects: 90
Study 17410029 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine (G)
Number of subjects: 90
Study 17410029 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine-carboplatin (GCb)
Number of subjects: 90
Study 15478362 — intervention group
Group type: EXPERIMENTAL
Intervention: rhBMP-2-augmented fusion
Number of subjects: 0
Study 15478362 — intervention group
Group type: COMPARATOR
Intervention: Autologous iliac crest bone graft (control)
Number of subjects: 0
Study 11479880 — intervention group
Group type: EXPERIMENTAL
Intervention: sICAM‐1 levels in group III (1760.0 ± 717.5 ng/mL)
Number of subjects: 35
Study 11479880 — intervention group
Group type: EXPERIMENTAL
Intervention: sVCAM‐1 levels in group III (1932.9 ± 282.6 ng/mL)
Number of subjects: 35
Study 11479880 — intervention group
Group type: EXPERIMENTAL
Intervention: sVCAM‐1 levels in group II with portal hypertension (PH) (1253.0 ± 245.1 ng/mL)
Number of subjects: 35
Study 11479880 — intervention group
Group type: EXPERIMENTAL
Intervention: Expression of ICAM‐1 and VCAM‐1
Number of subjects: 35
Study 9510981 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron mesylate, 200 mg after a high-fat breakfast
Number of subjects: 24
Study 9510981 — intervention group
Group type: COMPARATOR
Intervention: Dolasetron mesylate, 200 mg after an overnight fast
Number of subjects: 24
Study 9063763 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g. day-1 of allithiamine for 5 days
Number of subjects: 15
Study 9063763 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 5 days
Number of subjects: 15
Study 1946576 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (100 mg/kg/day)
Number of subjects: 20
Study 1946576 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (25 mg/kg/day)
Number of subjects: 20
Study 1946576 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (higher dose)
Number of subjects: 20
Study 1946576 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (both doses)
Number of subjects: 20
Study 7053279 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (240, 360, and 480 mg/day)
Number of subjects: 18
Study 7053279 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 31359053 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental cleaning bundle
Number of subjects: 11
Study 31359053 — intervention group
Group type: COMPARATOR
Intervention: Existing hospital cleaning practices
Number of subjects: 11
Study 30431384 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (IG) using the AlerHTA app, n = 77.
Number of subjects: 154
Study 30431384 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) with usual intervention, n = 77.
Number of subjects: 154
Study 30431384 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall adherence measured by electronic monitors (MEMSs).
Number of subjects: 154
Study 28011792 — intervention group
Group type: EXPERIMENTAL
Intervention: Humidified high flow nasal cannula (HFNC)
Number of subjects: 44
Study 28011792 — intervention group
Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (NCPAP)
Number of subjects: 44
Study 26595135 — intervention group
Group type: EXPERIMENTAL
Intervention: T+ (SUP)
Number of subjects: 27
Study 26595135 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric placebo (PL)
Number of subjects: 27
Study 24245960 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose prasugrel
Number of subjects: 106
Study 24245960 — intervention group
Group type: COMPARATOR
Intervention: Double maintenance-dose clopidogrel
Number of subjects: 106
Study 22586253 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterolane maleate plus piperaquine phosphate (AM-PQP) 150 mg and 750 mg respectively
Number of subjects: 240
Study 22586253 — intervention group
Group type: COMPARATOR
Intervention: Coartem (artemether and lumefantrine)
Number of subjects: 240
Study 22586253 — intervention group
Group type: EXPERIMENTAL
Intervention: Both AM-PQP and Coartem
Number of subjects: 240
Study 20356489 — intervention group
Group type: EXPERIMENTAL
Intervention: (125)I seeds implantation (n = 31)
Number of subjects: 66
Study 20356489 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 34)
Number of subjects: 66
Study 18341677 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolevamer potassium sodium 15 g day(-1) for 9 days
Number of subjects: 40
Study 18341677 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolevamer potassium sodium 6 g day(-1) for 9 days
Number of subjects: 40
Study 18341677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 15715683 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual ETA/ETB receptor antagonism with BQ123 and BQ788 (10 nmol min(‐1)) during ramipril treatment
Number of subjects: 37